Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
Author: Benzinga Newsdesk | April 09, 2024 12:00pm
The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Posted In: ATOS